Literature DB >> 30726711

Protective effects of febuxostat against paraquat-induced lung toxicity in rats: Impact on RAGE/PI3K/Akt pathway and downstream inflammatory cascades.

Maha A E Ahmed1, Engy M El Morsy2, Amany A E Ahmed2.   

Abstract

AIMS: The herbicide paraquat causes fatal lung toxicity by induction of xanthine oxidase, production of free radicals and inflammation. Febuxostat, a xanthine oxidase inhibitor and anti-gout has recently shown anti-inflammatory activity. Accordingly, this study was carried out to investigate whether febuxostat may attenuate paraquat-induced lung toxicity and to explore the possible underlying mechanisms. MAIN
METHODS: Rats were administered either vehicle, a single dose of paraquat (30 mg/kg, i.p.), febuxostat (15 mg/kg, oral), or both for 14 successive days. Serum LDH and sRAGE were estimated. Lung tissue xanthine oxidase activity, SOD, TAC, MDA, and RAGE, HMGB1 gene expression, PI3K/Akt and β-catenin protein expression, MMP-9, IL-8, VEGF and COX-2 gene expression were estimated. KEY
FINDINGS: Results showed that paraquat induced lung injury characterized by enhanced oxidative stress and inflammation, upregulated RAGE, HMGB1 gene expression, PI3K/Akt and β-catenin protein expression. Administration of febuxostat inhibited the deleterious effects of paraquat on lung through inhibition of xanthine oxidase activity and related oxidative stress, downregulation of RAGE/PI3K/Akt pathway, and suppression of β-catenin protein expression and its downstream inflammatory mediators. SIGNIFICANCE: The present study showed that febuxostat may abrogate paraquat-induced lung toxicity and demonstrated a novel mechanism for its ameliorative effects.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Akt; Febuxostat; HMGB1; Lung; PI3K; Paraquat; RAGE; β-Catenin

Mesh:

Substances:

Year:  2019        PMID: 30726711     DOI: 10.1016/j.lfs.2019.02.007

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  3 in total

1.  Pathophysiological Changes in Rhesus Monkeys with Paraquat-Induced Pulmonary Fibrosis.

Authors:  Mingyang Shao; Sha Yang; Aiyi Zheng; Zhenru Wu; Menglin Chen; Rong Yao; Yujun Shi; Gen Chen
Journal:  Lung       Date:  2022-09-26       Impact factor: 3.777

2.  Febuxostat therapy in outpatients with suspected COVID-19: A clinical trial.

Authors:  Lotfollah Davoodi; Seyed Mohammad Abedi; Ebrahim Salehifar; Reza Alizadeh-Navaei; Hamed Rouhanizadeh; Ghasemali Khorasani; Seyed Jalal Hosseinimehr
Journal:  Int J Clin Pract       Date:  2020-07-17       Impact factor: 3.149

Review 3.  Targeting inflammatory cytokine storm to fight against COVID-19 associated severe complications.

Authors:  Rishabh Hirawat; Mohd Aslam Saifi; Chandraiah Godugu
Journal:  Life Sci       Date:  2020-12-23       Impact factor: 6.780

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.